Before marketing a medical device or health product in the US,
or reintroducing a device that has been modified affecting safety or effectiveness,
manufacturers or parties of interest need to submit to the Food and Drug Administration FDA a pre market notification
510(k) and demonstrate by performance data and product documentation that it is substantially equivalent to
an already marketed device and that no new safety or effectiveness concerns are introduced. In case there is
no equivalente product cleared for marketing in the US, a premarket approval PMA submission might need to be followed.
In those cases clinical or animal test data might need to be submitted.
Sigma Biomedical provides complete regulatory consulting services for Food and Drug Administration (FDA) 510(k) submissions,
as well as for other medical regulatory affairs needs, such as FDA Quality System
Regulations QSR compliance. Sigma's regulatory, engineering and scientific team can efficiently help you achieve FDA Substantially
Equivalent notices.